Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE versus ESTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE versus ESTRONE.
ESTRADIOL VALERATE vs ESTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, a natural estrogen. Estrogens exert their effects by binding to estrogen receptors (ERα and ERβ), which act as transcription factors regulating gene expression. This leads to proliferation and growth of reproductive tissues, modulation of gonadotropin secretion, and effects on bone density, lipid metabolism, and other tissues.
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
1-2 mg orally once daily adjusted based on response; for hormone therapy, 5-20 mg intramuscularly every 4 weeks.
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
None Documented
None Documented
Clinical Note
moderateEstrone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Gatifloxacin."
Clinical Note
moderateEstrone sulfate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gatifloxacin."
Clinical Note
moderateEstrone + Rosoxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Rosoxacin."
Clinical Note
moderateEstrone sulfate + Rosoxacin
Terminal elimination half-life is approximately 12-14 hours after intramuscular administration, allowing for weekly or biweekly dosing intervals.
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
Renal (approximately 50% as glucuronide and sulfate conjugates), biliary/fecal (approximately 30-40% as conjugates), with enterohepatic circulation.
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Category D/X
Category C
Estrogen
Estrogen
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rosoxacin."